Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Fuji
Cipla
Fish and Richardson
Federal Trade Commission
Argus Health
Julphar

Generated: March 22, 2019

DrugPatentWatch Database Preview

Rucaparib camsylate - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for rucaparib camsylate and what is the scope of rucaparib camsylate patent protection?

Rucaparib camsylate is the generic ingredient in one branded drug marketed by Clovis Oncology Inc and is included in one NDA. There are ten patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Rucaparib camsylate has two hundred and thirty-six patent family members in fifty-two countries.

One supplier is listed for this compound.

Summary for rucaparib camsylate
International Patents:236
US Patents:10
Tradenames:1
Applicants:1
NDAs:1
Suppliers / Packagers: 1
Bulk Api Vendors: 12
Clinical Trials: 4
Patent Applications: 2
DailyMed Link:rucaparib camsylate at DailyMed
Pharmacology for rucaparib camsylate

US Patents and Regulatory Information for rucaparib camsylate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Clovis Oncology Inc RUBRACA rucaparib camsylate TABLET;ORAL 209115-003 May 1, 2017 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Clovis Oncology Inc RUBRACA rucaparib camsylate TABLET;ORAL 209115-003 May 1, 2017 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Clovis Oncology Inc RUBRACA rucaparib camsylate TABLET;ORAL 209115-001 Dec 19, 2016 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Supplementary Protection Certificates for rucaparib camsylate

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1633724 2015/016 Ireland ➤ Try a Free Trial PRODUCT NAME: OLAPARIB, AND SALTS AND SOLVATES THEREOF; REGISTRATION NO/DATE: EU/1/14/959/001 20141216
1633724 S1500012 Hungary ➤ Try a Free Trial PRODUCT NAME: OLAPARIB
1633724 C300726 Netherlands ➤ Try a Free Trial PRODUCT NAME: OLAPARIB, EN ZOUTEN EN; REGISTRATION NO/DATE: EU/1/14/959/001 20141216
Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Moodys
Cantor Fitzgerald
Merck
McKinsey
Johnson and Johnson
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.